These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8429246)

  • 1. [Etoposide/cis-platinum (CDDP) combined chemotherapy for ovarian cancer: evaluation of optimum schedule for CDDP administration in chronic continuous exposure of ovarian cancer cells to low-dose etoposide in vitro].
    Murakami F; Kiyozuka Y; Nishimura H; Imamura K; Yakushiji M; Noda T; Adachi S; Ito K; Tamori N; Shintani M
    Nihon Sanka Fujinka Gakkai Zasshi; 1993 Feb; 45(2):125-32. PubMed ID: 8429246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose optimization of gallium chloride, orally administered, in combination with platinum compounds.
    Collery P; Millart H; Kleisbauer JP; Paillotin D; Robinet G; Durand A; Claeyssens S; Legendre JM; Leroy A; Rousseau A
    Anticancer Res; 1994; 14(6A):2299-306. PubMed ID: 7825963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
    Lund B; Hansen OP; Hansen HH; Hansen M
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein kinase C inhibitor Gö6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum-II (CDDP) in a human ovarian cancer model.
    Qamar L; Davis R; Anwar A; Behbakht K
    Gynecol Oncol; 2008 Sep; 110(3):425-31. PubMed ID: 18619662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
    Tanaka T; Masuda H; Naito M; Tamai H
    Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Preliminary report on the effect of etoposide or etoposide and CDDP on recurrent prostate cancer].
    Suzuki K; Nakamura T; Kato N; Kurita M; Nakazawa Y; Suzuki T; Imai K; Yamanaka H
    Hinyokika Kiyo; 1991 Nov; 37(11):1499-503. PubMed ID: 1767772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of recurrent ovarian cancer].
    Kudo R; Sagae S
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):1991-7. PubMed ID: 1358032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy with cisplatin, etoposide and gallium chloride for lung cancer: individual adaptation of doses.
    Collery P; Morel M; Desoize B; Millart H; Perdu D; Prevost A; Vallerand H; Pechery C; Choisy H; Etienne JC
    Anticancer Res; 1991; 11(4):1529-32. PubMed ID: 1660690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [CDDP-ACR treatment in patients with recurrent ovarian cancer with prior chemotherapy containing CDDP--a preliminary study of a 14-day continuous infusion of CDDP with ACR].
    Chen JT; Hirai Y; Nakayama K; Shimizu Y; Yokosuka K; Teshima H; Hamada T; Fujimoto I; Yamauchi K; Hasumi K
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Oct; 41(10):1565-70. PubMed ID: 2584809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the use of chronic low-dose oral etoposide in ovarian cancer: is there a role for this "new drug" in the management of platinum-refractory disease?
    Markman M; Hakes T; Reichman B; Barakat R; Curtin J; Jones W; Lewis JL; Rubin S; Almadrones L; Hoskins W
    Semin Oncol; 1992 Dec; 19(6 Suppl 14):25-7. PubMed ID: 1488652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case report of an advanced ovarian cancer (stage T4) treated with a total amount of 1815 mg of CDDP].
    Maruyama M; Noda T; Kiyozuka Y; Okamura Y; Ibaraki T; Katou Y; Ninomiya Y; Oku M; Nabuchi K; Hino K
    Gan No Rinsho; 1987 Oct; 33(12):1507-14. PubMed ID: 3119892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Consecutive intra-arterial infusion of cis-diamminedichloroplatinum with continuous intra-arterial infusion of 5-fluorouracil in locally advanced ovarian cancer].
    Shimizu Y; Fujiwara A; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
    Gan To Kagaku Ryoho; 1986 May; 13(5):1934-9. PubMed ID: 3707153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combination chemotherapy with 5-FU and CDDP or CDDP analog for head and neck cancer].
    Fujii M; Ohno Y; Tokumaru Y; Imanishi Y; Kanke M
    Gan To Kagaku Ryoho; 1996 Nov; 23(13):1740-6. PubMed ID: 8937483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intraperitoneal chemotherapy of CDDP and etoposide in patients with advanced ovarian cancer].
    Hirashima Y; Shimura T; Tanaka Y; Demukai H; Kubota T; Kobayashi T; Suzuki A
    Gan To Kagaku Ryoho; 1993 Aug; 20(10):1321-6. PubMed ID: 8346930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of melatonin on the proliferation and cis-diamminedichloroplatinum (CDDP) sensitivity of cultured human ovarian cancer cells.
    Futagami M; Sato S; Sakamoto T; Yokoyama Y; Saito Y
    Gynecol Oncol; 2001 Sep; 82(3):544-9. PubMed ID: 11520153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combination therapy of a novel oral fluorouracil derivative TS-1 with low-dose cisplatin for recurrent and very advanced gastric cancer].
    Nakata B; Hirakawa K
    Gan To Kagaku Ryoho; 2004 Nov; 31(12):1962-8. PubMed ID: 15570921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Etoposide (VP-16) in gynecologic malignancy].
    Kanazawa K; Moromizato H
    Gan To Kagaku Ryoho; 1996 Dec; 23(14):1925-8. PubMed ID: 8978799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
    Rose PG; Rodriguez M; Walker J; Greer B; Fusco N; McGuire W
    Gynecol Oncol; 2002 Apr; 85(1):136-9. PubMed ID: 11925133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Successful treatment of a patient with recurrent ovarian clear cell adenocarcinoma under combination chemotherapy of 5-FU (civ) and low-dose CDDP (i.v.)].
    Sakaihara M; Sakai K; Hara Y; Kataoka S; Tabata M; Hanatani K; Hareyama H
    Gan To Kagaku Ryoho; 2000 Jan; 27(1):127-30. PubMed ID: 10660745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.